Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pathophysiological-based treatments of complications of cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The clinical course of common bile duct stone clearance with endoscopic retrograde cholangio-pancreaticography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Oral D/L-3-Hydroxybutyrate stimulates cholecystokinin and insulin secretion and slows gastric emptying in healthy males

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of insulin on natriuretic peptide gene expression in porcine heart

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Objective: The incidence of enteropancreatic neuroendocrine tumours (NET) is increasing. Chromogranin A (CgA) in plasma is a marker in patients suspected of NET tumours. CgA, however, is a precursor protein subjected to cellular processing that challenges quantitation and hence the use of CgA in diagnostics.Materials and methods: CgA concentrations in plasma sampled from 130 well-characterized patients with small intestinal NETs and from 30 healthy subjects were measured with eight commercial CgA kits, an in-house radioimmunoassay (RIA) and a processing-independent assay (PIA). For the evaluation of diagnostic accuracy, we performed regression analyses and plotted receiver-operating characteristic curves (ROC). The specificity was further assessed by size chromatography.Results: Five commercial assays (Thermo-Fisher, DRG Diagnostics, Eurodiagnostica (RIA and ELISA), and Phoenix), displayed a diagnostic accuracy with area under the curve (AUC) values >0.90, whereas three immunoassays (Yanaihara, CisBio RIA, and CisBio ELISA) discriminated poorly between disease stages (AUC: 0.60-0.78). Compared with the in-house assays, however, even the most accurate commercial immunoassay still missed patients with metastatic disease. Chromatography showed non-uniform patterns of large and small CgA fragments in plasma.Conclusion: Available commercial immunoassays measure CgA in plasma with gross variability. Three commercial CgA immunoassays discriminate so poorly between health and disease that they should not be used. The highest diagnostic accuracy was obtained with processing-independent measurement of total CgA concentrations in plasma.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Gastroenterology
Vol/bind55
Udgave nummer5
Sider (fra-til)565-573
Antal sider9
ISSN0036-5521
DOI
StatusUdgivet - 2020

ID: 60068656